ArticleEuropean journal of immunology2026
Cytomegalovirus-Based Viral Vectors Elicit Robust Systemic and Tissue-Resident Immune Response Against SARS-CoV-2 Antigens.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytomegalovirus-Based Viral Vectors Elicit Robust Systemic and Tissue-Resident Immune Response Against SARS-CoV-2 Antigens.European journal of immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Current COVID-19 vaccines face challenges such as waning immunity and limited mucosal protection. These limitations highlight the importance of developing next-generation vaccines that can induce strong tissue-specific and systemic immune responses. Cytomegalovirus (CMV) represents a promising vaccine vector due to its ability to elicit robust and durable immunity. In this study, we generated murine CMV (MCMV)-based vaccine vectors expressing the SARS-CoV-2 spike (S) protein using either a wild-type or immunologically attenuated viral strain. By comparing intraperitoneal (IP) and intranasal (IN) immunization with both MCMV vectors, we show that IP administration induced higher, long-lasting S-specific antibody levels in serum. Both routes elicited strong systemic S-specific CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.